Heidelberg Pharma AG

As of May 31, 2026, Heidelberg Pharma AG carries a market capitalization of 124.91M, placing it among publicly traded companies globally. Its enterprise value stands at 100.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Heidelberg Pharma AG's next confirmed earnings release is scheduled for February 3, 2027.

As of May 31, 2026, Heidelberg Pharma AG has 46.78M shares outstanding.

These figures are as of May 31, 2026. The price-to-sales ratio is 16.67, and the price-to-book ratio stands at -8.78.

These figures are as of May 31, 2026. The EV/Sales ratio of 13.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 100.03M versus a market cap of 124.91M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, Heidelberg Pharma AG maintains a current ratio of 5.29, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -0.32, indicating conservative leverage, while an interest coverage ratio of -8,303.62 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended May 31, 2026. Return on assets (ROA) is negative at -62.77, reflecting losses generated across the asset base. The company generates approximately 63,164.64 in revenue per employee across its workforce of 119.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.08 indicates how many times Heidelberg Pharma AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended May 31, 2026, Heidelberg Pharma AG recorded 1.48M in income tax expense. The company reported a pretax loss of -29.82M and -31.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Heidelberg Pharma AG's stock has declined approximately 30.00% over the past 52 weeks. The 50-day moving average sits at 2.43, while the 200-day moving average is 2.70.

Over the twelve months ended May 31, 2026, Heidelberg Pharma AG generated 7.52M in revenue and converted that into -31.29M in net income, yielding earnings per share of -0.67. EBITDA reached -27.88M, while operating income came in at -34.17M.

As of May 31, 2026, Heidelberg Pharma AG holds 24.93M in cash and equivalents against 45,985.00 in total debt, resulting in a net debt position of -24.93M. Total book value stands at -14.22M, with working capital of 30.68M providing operational flexibility.

Heidelberg Pharma AG produced -19.62M in operating cash flow over the twelve months ended May 31, 2026. After subtracting 72,971.00 in capital expenditures, free cash flow totaled -19.55M - equivalent to -0.42 per share.

Over the twelve months ended May 31, 2026, Heidelberg Pharma AG posted a gross margin of 88.08, reflecting its pricing power and cost economics. The operating margin of -454.58 and net profit margin of -416.32 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -15.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.75, meaning Heidelberg Pharma AG raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Heidelberg Pharma AG's most recent stock split took place on November 7, 2017.

As of May 31, 2026, Heidelberg Pharma AG has an Altman Z-Score of -14.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.